Increased hippocampal glutamate and volumetric deficits in unmedicated patients with schizophrenia.
about
Translating the MAM model of psychosis to humansIn vivo assessment of neurotransmitters and modulators with magnetic resonance spectroscopy: application to schizophreniaGlutamatergic abnormalities in schizophrenia: a review of proton MRS findings.[Neurobiology of schizophrenia: new findings from the structure to the molecules].Glutamate-mediated excitotoxicity in schizophrenia: a review.Imaging-based neurochemistry in schizophrenia: a systematic review and implications for dysfunctional long-term potentiationIsolating pathogenic mechanisms embedded within the hippocampal circuit through regional vulnerability.Feasibility and reproducibility of neurochemical profile quantification in the human hippocampus at 3 T.Functional and clinical insights from neuroimaging studies in childhood-onset schizophrenia.Cortico-Striatal GABAergic and Glutamatergic Dysregulations in Subjects at Ultra-High Risk for Psychosis Investigated with Proton Magnetic Resonance Spectroscopy.In SilicoModel-driven Assessment of the Effects of Brain-derived Neurotrophic Factor Deficiency on Glutamate and Gamma-Aminobutyric Acid: Implications for Understanding Schizophrenia Pathophysiology.Brain structure, function, and neurochemistry in schizophrenia and bipolar disorder-a systematic review of the magnetic resonance neuroimaging literature.Relationship between brain glutamate levels and clinical outcome in individuals at ultra high risk of psychosis.GABA and glutamate in schizophrenia: a 7 T ¹H-MRS study.Ketamine and phencyclidine: the good, the bad and the unexpected.GABAergic mechanisms of hippocampal hyperactivity in schizophrenia.Glutamatergic neurometabolites in clozapine-responsive and -resistant schizophreniaDecoupling of N-acetyl-aspartate and glutamate within the dorsolateral prefrontal cortex in schizophreniaSupplementation of Antipsychotic Treatment with the Amino Acid Sarcosine Influences Proton Magnetic Resonance Spectroscopy Parameters in Left Frontal White Matter in Patients with Schizophrenia.Comparison of Metabolite Concentrations in the Left Dorsolateral Prefrontal Cortex, the Left Frontal White Matter, and the Left Hippocampus in Patients in Stable Schizophrenia Treated with Antipsychotics with or without Antidepressants. ¹H-NMR SpectN-acetylaspartate normalization in bipolar depression after lamotrigine treatmentAbnormalities in large scale functional networks in unmedicated patients with schizophrenia and effects of risperidone.Contribution of substantia nigra glutamate to prediction error signals in schizophrenia: a combined magnetic resonance spectroscopy/functional imaging study.Elevated Myo-Inositol, Choline, and Glutamate Levels in the Associative Striatum of Antipsychotic-Naive Patients With First-Episode Psychosis: A Proton Magnetic Resonance Spectroscopy Study With Implications for Glial Dysfunction.Cross-sectional Study of Glutamate in the Anterior Cingulate and Hippocampus in Schizophrenia.Change in brain network topology as a function of treatment response in schizophrenia: a longitudinal resting-state fMRI study using graph theory.Aberrant Hippocampal Connectivity in Unmedicated Patients With Schizophrenia and Effects of Antipsychotic Medication: A Longitudinal Resting State Functional MRI Study.Deficits in striatal dopamine release in cannabis dependence.Elevated brain lactate in schizophrenia: a 7 T magnetic resonance spectroscopy study.Risperidone Effects on Brain Dynamic Connectivity-A Prospective Resting-State fMRI Study in Schizophrenia.Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials.Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis.Ketamine modulates hippocampal neurochemistry and functional connectivity: a combined magnetic resonance spectroscopy and resting-state fMRI study in healthy volunteersPalmitoylethanolamide Modulates GPR55 Receptor Signaling in the Ventral Hippocampus to Regulate Mesolimbic Dopamine Activity, Social Interaction, and Memory Processing.Glutamatergic Metabolites, Volume and Cortical Thickness in Antipsychotic-Naive Patients with First-Episode Psychosis: Implications for Excitotoxicity.Prognostic factor from MR spectroscopy in rat with astrocytic tumour during radiation therapy.A fundamental role for hippocampal parvalbumin in the dopamine hyperfunction associated with schizophrenia.Altered Glutamate and Regional Cerebral Blood Flow Levels in Schizophrenia: A 1H-MRS and pCASL study.The bumps under the hippocampus.Prefrontal and Striatal Gamma-Aminobutyric Acid Levels and the Effect of Antipsychotic Treatment in First-Episode Psychosis Patients.
P2860
Q26860217-8200A3E2-52D3-4622-82D9-347AAB700235Q28083121-A016CEB6-6FC6-4B22-8381-AE2B6DA90FBFQ30732395-075E7133-52C0-4119-B0AB-6E2063C76D26Q30842754-A4C2CFF4-3881-4D19-8363-B95E67C42B68Q30845062-B61B079A-F37A-40AB-A093-2EC59A552166Q30854782-CA844820-4F92-4309-8C86-AAC700F4889AQ30857122-A0E48FE1-8BEF-461A-86DF-F5FB733240D5Q30938690-838F9920-5FFF-4513-A037-3533DDDB0077Q30984507-1F69B177-B470-4C3D-BBBC-EF1958651600Q30993265-1A482A9B-254D-4913-92D6-0BA1D78C1C48Q33662831-0C476E34-6C8C-423E-89CB-46F835F5A7E4Q33718818-236F4791-D53F-4354-9400-CF4C4C04174DQ34270086-4170A237-F522-45DD-AC45-9F3D0096B358Q34446463-E7E310A3-1577-4ED1-AE5E-F9348C1DD574Q34480719-C8A95434-906E-4EF3-8C64-E64500BFB1C1Q35469889-FC08A1C3-CA51-48B4-98AC-891B63B26906Q35626964-520B02B5-D649-4917-A4FF-53CE781DE847Q35872055-E3A74E38-DBAF-49E2-880F-9BBBC4E37CDDQ36246819-812C5D9B-D9B0-486F-91DF-4C1A8F789C0EQ36247410-94D90D70-D78B-4B50-AD55-7C14B53FBFD9Q36306253-BF9F036B-85DB-408D-A139-191941A7280DQ36382573-82356C48-AD83-4CF6-B0FF-CA083AF93566Q36575926-3F5E267F-1A31-4245-92ED-117CF7CDD778Q36579965-A372C40D-4669-457B-BCA3-491E14ACB26EQ36579976-6256B180-B9D5-4D1B-BFC1-3B3A6B6A31E3Q36983379-9715795C-2A06-45FB-A44B-0FC86B1870D5Q36994859-EC1B49D7-3D1E-4B7C-B261-A132A71EFE2BQ37276855-0FA85825-A2DF-440B-80EA-D373C8566F89Q37622674-BEFE2BDE-94E6-44EB-9BD5-C0C245D7A896Q37625470-137A3324-0655-4645-879E-289262439854Q37662441-6E900189-A808-4248-BBA3-86A966D00F69Q39130393-FCC532BD-1ACF-42A5-9D44-9DF48950167CQ39536837-F5B56545-AADE-47E0-9C88-4EA94399433AQ41152448-7463BD2A-A7CA-432D-98FF-1548DD1B211EQ41724967-ED2D994D-A3BC-41A9-A319-DCD4DB00A5F0Q41843586-5940C3FD-DE40-46CF-B957-9431B7873338Q41994285-74B2EA55-B4E9-4035-ACAC-FA27B070B848Q43538712-DE86B969-F7C0-4D7F-B490-4200521ADF84Q47421914-2D7E2402-EC19-4F13-8919-60D0F0D5E6BCQ47574865-C907A7F6-57B2-41E0-B482-D88B2FC9C93C
P2860
Increased hippocampal glutamate and volumetric deficits in unmedicated patients with schizophrenia.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Increased hippocampal glutamat ...... d patients with schizophrenia.
@en
Increased hippocampal glutamat ...... d patients with schizophrenia.
@nl
type
label
Increased hippocampal glutamat ...... d patients with schizophrenia.
@en
Increased hippocampal glutamat ...... d patients with schizophrenia.
@nl
prefLabel
Increased hippocampal glutamat ...... d patients with schizophrenia.
@en
Increased hippocampal glutamat ...... d patients with schizophrenia.
@nl
P50
P1433
P1476
Increased hippocampal glutamat ...... d patients with schizophrenia.
@en
P2093
Adrienne C Lahti
P304
P356
10.1001/JAMAPSYCHIATRY.2013.2437
P407
P577
2013-12-01T00:00:00Z